Choose your country to see the products for your location
Some of our products have a new, neutrally coloured packaging to highlight the use of these products across different MRC Holland technologies
We would like to remind our non-EU customers who order directly from MRC Holland that we are required to add a surcharge of €0.01 on Sample DNAs (SDs) that are included as accessory items with selected MLPA assays.
August is SMA Awareness Month! Spinal Muscular Atrophy (SMA) is a neuromuscular disease where the body loses control over the muscle movements. Early detection and treatment of SMA are vital for improved outcomes.
Today is Glioblastoma Awareness Day, highlighting the need for improved treatment options for this aggressive type of brain cancer.
We are excited to announce the release of our comprehensive digitalMLPA data sets, showcasing sample data from various SALSA® digitalMLPA™ applications: D001 Hereditary Cancer, D006 Multiple Myeloma and D007 Acute Lymphoblastic Leukemia.
In a recent research article published in the British Journal of Cancer, Bedics et al. developed a new B-ALL classifier using SALSA digitalMLPA Probemix D007 Acute Lymphoblastic Leukemia.
We are glad to inform you that we have released an improved version of SALSA® MLPA® Probemix ME029 FMR1-AFF2, accompanied by a new product-specific protocol.
We are glad to announce the launch of ME053 BRCA1-BRCA2-RAD51C.
SALSA MC002 SMA Newborn Screen, SALSA digitalMLPA Probemix D001 Hereditary Cancer Panel 1 and SALSA MLPA Probemix P008 PMS2 were the products with the largest growth compare to 2021.
For non-EU customers who order directly from MRC Holland, we are required to add a surcharge of €0.01 on Sample DNAs (SDs) that are included as accessory items with selected MLPA assays.
Join our mailing list to receive the latest information about our products, technologies and website.